Publications by authors named "Jean Marc Sobhy Danial"
Janus kinase inhibitors (JAKis) belong to a new class of targeted oral drugs that have been added to the therapeutic arsenal for rheumatoid arthritis (RA). The aim of this study was to evaluate the efficacy and safety profiles of these four available molecules (tofacitinib, baricitinib, filgotinib, and upadacitinib) in real life. A retrospective, single-center observational study including all patients treated with JAKis for RA from 1 October 2017 to 1 December 2023.
View Article and Find Full Text PDFArticle Synopsis
- - The study examined 132 patients with psoriatic arthritis (PsA) to understand its clinical, biological, and imaging characteristics, focusing on differences between men and women.
- - Key findings included that peripheral PsA was the most common form, with notable occurrences of enthesitis (52.3%) and dactylitis (29.5%), and gender disparities showed that women experienced more polyarticular forms and treatment with disease-modifying drugs, while men had more chronic hyperuricemia and nail disorders.
- - The conclusion emphasized the heterogeneous nature of PsA and the importance of recognizing associated axial involvement, which is often overlooked, to improve patient management.
Background: Drug persistence reflects an agent’s efficacy and safety in routine practice. This study was undertaken to compare the 2-year persistence rates of three biologic disease-modifying antirheumatic drugs (bDMARDs) used to treat rheumatoid arthritis (RA) and to describe their efficacy and safety profiles. Methods: This retrospective, observational, single-center study included RA patients who had received at least one intravenous dose of infliximab, abatacept, and/or tocilizumab.
View Article and Find Full Text PDFArticle Synopsis
- Cardiovascular disease, especially heart attacks, is the main cause of death in patients with rheumatoid arthritis (RA), prompting a study to evaluate the coronary artery calcification score (CACS) in these patients.
- The study involved 50 patients with stable or remitted RA and included a range of cardiovascular tests, aiming to see how many had a CACS over 100, indicating serious atherosclerosis.
- Results showed 24% of patients had a high CACS, leading to a reclassification of cardiovascular risk in some cases, with significant factors being age, sex, and smoking status, but no link was found to RA treatments.
Background: Janus kinase inhibitors (JAKis) represent a new alternative to treat rheumatoid arthritis (RA). The objective of this study was to evaluate the effectiveness, tolerance profile, and maintenance of these treatments (tofacitinib and baricitinib) in real life.
Methods: All patients in the rheumatology department of Amiens University Hospital treated by JAKis for RA were included from 1 October 2017 to 20 May 2020.